FCCC LOGO Faculty Publications
McGuire WP , Brady MF , Ozols RF
The Gynecologic Oncology Group experience in ovarian cancer
Annals of Oncology. 1999 ;10 :29-34
PMID: ISI:000080354700006   
Back to previous list
Abstract
Trials performed in the past 15 years by the Gynecologic Oncology Group identified as optimal a platinum/taxane combination as the backbone to treat chemonaive ovarian cancer. Comparison to a triplet adding a third drug to the backbone is least likely to significantly improve outcome, however, of the drugs currently available for addition; doxil, etoposide, gemcitabine, and topotecan; none appears to be any better or worse than was paclitaxel a decade ago. An approach more likely to improve outcome would be to incorporate as many of these "new" drugs as possible using sequential doublets. Some doublets have a better biochemical rationale such as cisplatin and gemcitabine (inhibition of DNA repair) or topotecan and either doxil or etoposide (upregulation of topoisomerase II levels by topotecan followed by a topoisomerase II inhibitor.
Notes
Times Cited: 5 English Article 1 197FN ANN ONCOL